Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$50.68
+0.4%
$57.71
$39.35
$63.33
$103.11B0.4112.92 million shs13.41 million shs
MyoKardia, Inc. stock logo
MYOK
MyoKardia
$224.91
$224.61
$42.65
$225.00
$11.99B1.84752,969 shsN/A
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
+0.44%-8.40%-15.29%-9.25%+0.78%
MyoKardia, Inc. stock logo
MYOK
MyoKardia
0.00%0.00%0.00%0.00%0.00%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.7013 of 5 stars
3.25.04.24.02.83.30.0
MyoKardia, Inc. stock logo
MYOK
MyoKardia
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.32
Hold$57.6713.80% Upside
MyoKardia, Inc. stock logo
MYOK
MyoKardia
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BMY and MYOK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$60.00 ➝ $54.00
4/8/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$67.00 ➝ $55.00
2/7/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$60.00 ➝ $62.00
2/4/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$50.00 ➝ $55.00
1/28/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$60.00 ➝ $65.00
(Data available from 4/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$48.30B2.13$5.35 per share9.48$8.08 per share6.27
MyoKardia, Inc. stock logo
MYOK
MyoKardia
$33.56M357.36N/AN/A$8.79 per share25.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$8.95B-$4.42N/A8.322.07-18.53%13.93%2.46%4/24/2025 (Estimated)
MyoKardia, Inc. stock logo
MYOK
MyoKardia
-$276.21M-$4.38N/AN/AN/AN/A-47.99%-42.42%N/A

Latest BMY and MYOK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2025Q1 2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.55N/AN/AN/A$10.77 billionN/A
2/6/2025Q4 2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.47$1.67+$0.20$0.04$11.57 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.484.89%+6.38%N/A 17 Years
MyoKardia, Inc. stock logo
MYOK
MyoKardia
N/AN/AN/AN/AN/A

Latest BMY and MYOK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/3/2025
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.624.14%4/4/20254/4/20255/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.90
1.25
1.15
MyoKardia, Inc. stock logo
MYOK
MyoKardia
N/A
21.03
21.03

Institutional Ownership

CompanyInstitutional Ownership
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%
MyoKardia, Inc. stock logo
MYOK
MyoKardia
N/A

Insider Ownership

CompanyInsider Ownership
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
MyoKardia, Inc. stock logo
MYOK
MyoKardia
4.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,3002.03 billion2.03 billionOptionable
MyoKardia, Inc. stock logo
MYOK
MyoKardia
31853.32 millionN/AOptionable

Recent News About These Companies

Palace Hotel buffet
BK8 slot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bristol-Myers Squibb stock logo

Bristol-Myers Squibb NYSE:BMY

$50.68 +0.22 (+0.43%)
Closing price 04/11/2025 03:59 PM Eastern
Extended Trading
$50.44 -0.23 (-0.45%)
As of 04/11/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

MyoKardia stock logo

MyoKardia NASDAQ:MYOK

MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.